Edward R. Jones reports sale of 88,834 CTSO shares and $1 options
Rhea-AI Filing Summary
CytoSorbents director Edward R. Jones reported a change in beneficial ownership showing a disposition of 88,834 shares of Common Stock on 08/08/2025. The filing states that the 88,834 shares comprise 69,300 Restricted Stock Units (grants from 2015, 2016, 2017 and 2018 that vest on a defined "Change In Control") and 19,534 shares owned outright by the reporting person. The filing also shows an acquisition of 22,000 stock options granted under the company plan with a $1 exercise price; those options vest in four equal quarterly installments over one year following grant and appear to expire on 08/08/2035. The Form 4 was submitted as a single reporting person filing and includes a Power of Attorney exhibit.
Positive
- Option grant: Reporting person acquired 22,000 stock options at a $1 exercise price with vesting in four equal quarterly installments over one year and expiration on 08/08/2035.
- Transparency: Filing discloses composition of disposed shares, including specific RSU grant counts and grant dates.
Negative
- Disposition: Reporting person disposed of 88,834 shares of Common Stock on 08/08/2025.
- RSU contingent on Change In Control: 69,300 of the disclosed units vest only upon a defined Change In Control, indicating conditional value realization.
Insights
TL;DR: Director reported a large disposition of 88,834 shares and received 22,000 options at $1 with one-year vesting.
The reported disposal of 88,834 common shares is material at a transactional level and is notable because a significant portion (69,300 shares) are RSUs tied to a "Change In Control." Separately, the grant of 22,000 stock options at a $1 strike that vest quarterly over one year aligns management incentives with future stock performance; expiration is listed as 08/08/2035. Absent company-wide context or relative ownership percentages, the net impact on shareholder value is ambiguous, so this filing is best viewed as a routine insider transaction with mixed signals.
TL;DR: Insider action mixes a sizeable disposal (including change-in-control RSUs) with a time‑based option grant; governance implications are mixed.
The disclosure that 69,300 RSUs vest only upon a defined Change In Control and that 19,534 shares were owned outright clarifies the composition of the 88,834-share disposition. The contemporaneous grant of 22,000 options with one-year vesting suggests continued alignment incentives for the reporting person. From a governance perspective, the form is transparent about grant structure and vesting conditions; however, without proportional ownership data or company context this remains an informational disclosure rather than a materially decisive governance event.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 22,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes: (i) the following Restricted Stock Units ("RSUs") that will be settled into Common Stock vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person. The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.
